- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07742579
Online Mindfulness-Based Cognitive Therapy for People With Multiple Sclerosis With Mild-Moderate Depression
Online Mindfulness-Based Cognitive Therapy for People With Multiple Sclerosis With Mild-Moderate Depression: A Hybrid Effectiveness-Implementation Study
This study will use a waiting list randomized controlled trial design with a mixed-methods research approach, including both quantitative and qualitative methods. Randomization helps minimize research bias and controls for participant and contextual factors that might otherwise make interpretation of results challenging. We will recruit 152 people with multiple sclerosis (PwMS) with any type of MS, who also have mild-moderate depression, aged 18 or greater, and able to understand spoken and written English.
For the quantitative part, we will examine how much change in depression there is following mindfulness-based cognitive therapy (MBCT), as well as whether participants attend the course and complete study measures or not, and how much participants complete MBCT home practices. We will also examine how much change there is in fatigue, sleep pain, quality of life, and anxiety.
For the qualitative part of the study, we will use semi-structured interviews to explore participant experiences of online MBCT, how people used online MBCT, what worked, what didn't and why, how online MBCT impacted self-management of depression, and suggestions for improving the course to make it more relevant for PwMS with depression.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Robert Simpson
- Telefonnummer: 416-978-8383
- E-post: rab.simpson@utoronto.ca
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion criteria will include:
- Age >/=18
- Neurologist confirmed MS diagnosis (McDonald criteria)
- Able to understand spoken and written English
- A score of 14-28 on the Beck Depression Inventory-II signifying mild-moderate depression
- Registered with a primary care provider (family physician or neurologist)
- Residing in Canada
Exclusion criteria will include:
- Potentially life-threatening comorbidities (suicidal ideation (i.e., score of 2 or 3 on the BDI-Fast Screen suicidal ideation question), history of psychosis, terminal/life threatening inter-current illness), or those such conditions expected to significantly limit participation and adherence (pregnancy, cognitive impairment i.e. score <26 on the Montreal Cognitive Assessment - MoCA)
- Receipt of MBCT in the past 2 years (completed at least 4/8 sessions).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Mindfulness-Based Cognitive Therapy
Online group Mindfulness-Based Cognitive Therapy delivered live online in weekly sessions for 8 weeks
|
Online group Mindfulness-Based Cognitive Therapy delivered live online in weekly sessions for 8 weeks
|
|
Inget ingripande: Waitlist control
Waitlist control arm - participants receive no intervention initially but receive MBCT following data collection
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Depression
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Change in depression scores using the Hospital Anxiety and Depression Scale
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Self-efficacy
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Self-efficacy, as measured by the Generalized Self-Efficacy Scale
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Self-management
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Self-management, as measured by the Multiple-Sclerosis Self-Management Scale-Revised
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Stigma
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Stigma, as measured by the Stigma Scale for Chronic Illness-8
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Fatigue
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Fatigue as measured by the Modified Fatigue Impact Scale
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Sleep
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Sleep as measured by the Insomnia Severity Index
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Change in pain
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Pain as measured by the Pain Effects Scale
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Change in quality of life
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Quality of life as measured by the Multiple Sclerosis Impact Scale-29
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Anxiety
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Anxiety as measured by Hospital Anxiety and Depression Scale -Anxiety
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Mindfulness
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Mindfulness as measured by The Five-facet Mindfulness Questionnaire
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Self-compassion
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Self-compassion, measured using the The Self-Compassion Scale-short form
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Emotion regulation
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Emotion regulation, as measured by The Difficulties with Emotional Regulation Scale short-form
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Group attendance
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Group attendance in those allocated to tailored online MBCT
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Group climate
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Group climate using the Climate Questionnaire-Engage Scale
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Therapeutic alliance
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Therapeutic alliance as measured by the Working Alliance Inventory
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Depressive symptoms
Tidsram: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
Depressive symptoms as measured by the Beck Depression Inventory II (BDI-II)
|
Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
|
|
Implementation
Tidsram: Throughout the study and up to 12 months post-intervention
|
Implementation, as informed by the Proctor's taxonomy
|
Throughout the study and up to 12 months post-intervention
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Sjukdomar i nervsystemet
- Autoimmuna sjukdomar
- Immunsystemets sjukdomar
- Demyeliniserande autoimmuna sjukdomar, CNS
- Autoimmuna sjukdomar i nervsystemet
- Demyeliniserande sjukdomar
- Multipel skleros
- Beteendebehandling
- Psykoterapi
- Beteendediscipliner och aktiviteter
- Kognitiv beteendeterapi
- Medvetenhet
- Mindfulness-baserad kognitiv terapi
Andra studie-ID-nummer
- 00049655
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .